1- Briot K, Cortet B, Thomas T, et al. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. J Bone Spine 2012; 79(3): 264-74.
2- Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with lowtrauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009;301:513–21
3- Benhamou CL, Souberbielle JC, Cortet B et al. La vitamine D chez l’adulte : recommandations du GRIO. Presse Médicale 2011;40 :673-682.
4- Black DM, Bauer DC, Schwartz AV, et al. Continuing Bisphosphonate Treatment for Osteoporosis - For Whom and for How Long ? N Engl J Med. 2012; 366: 2051-3.
5- Kendler DL,. Roux Ch, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25:72-81
Mise au point
La périménopause
Mise au point
La sclérose en plaques
Etude et Pratique
Appendicite aiguë de l’enfant : chirurgie ou antibiotiques ?
Mise au point
Le suivi des patients immunodéprimés en soins primaires